86 related articles for article (PubMed ID: 12826311)
1. New insights in beta-tubulin sequence analysis in non-small cell lung cancer.
de Castro J; Belda-Iniesta C; Cejas P; Casado E; Fresno Vara JA; Hardisson D; Sánchez JJ; Feliu J; Ordóñez A; Nistal M; González-Barón M
Lung Cancer; 2003 Jul; 41(1):41-8. PubMed ID: 12826311
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Monzó M; Rosell R; Sánchez JJ; Lee JS; O'Brate A; González-Larriba JL; Alberola V; Lorenzo JC; Núñez L; Ro JY; Martín C
J Clin Oncol; 1999 Jun; 17(6):1786-93. PubMed ID: 10561216
[TBL] [Abstract][Full Text] [Related]
3. Absence of beta-tubulin gene mutation in gastric carcinoma.
Urano N; Fujiwara Y; Hasegawa S; Miyoshi Y; Noguchi S; Takiguchi S; Yasuda T; Yano M; Monden M
Gastric Cancer; 2003; 6(2):108-12. PubMed ID: 12861402
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
5. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.
Sale S; Sung R; Shen P; Yu K; Wang Y; Duran GE; Kim JH; Fojo T; Oefner PJ; Sikic BI
Mol Cancer Ther; 2002 Jan; 1(3):215-25. PubMed ID: 12467216
[TBL] [Abstract][Full Text] [Related]
6. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Tsai CM; Chen JT; Stewart DJ; Chiu CH; Lai CL; Hsiao SY; Chen YM; Chang KT
J Thorac Oncol; 2011 Mar; 6(3):559-68. PubMed ID: 21258258
[TBL] [Abstract][Full Text] [Related]
7. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
[TBL] [Abstract][Full Text] [Related]
8. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
[TBL] [Abstract][Full Text] [Related]
9. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.
Sève P; Mackey J; Isaac S; Trédan O; Souquet PJ; Pérol M; Lai R; Voloch A; Dumontet C
Mol Cancer Ther; 2005 Dec; 4(12):2001-7. PubMed ID: 16373715
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
[TBL] [Abstract][Full Text] [Related]
13. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
14. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the beta-tubulin gene in lung cancer.
Tsurutani J; Komiya T; Uejima H; Tada H; Syunichi N; Oka M; Kohno S; Fukuoka M; Nakagawa K
Lung Cancer; 2002 Jan; 35(1):11-6. PubMed ID: 11750707
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
[TBL] [Abstract][Full Text] [Related]
17. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
Gan PP; Pasquier E; Kavallaris M
Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044
[TBL] [Abstract][Full Text] [Related]
18. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
Wehbe H; Kearney CM; Pinney KG
Anticancer Res; 2005; 25(6B):3865-70. PubMed ID: 16309172
[TBL] [Abstract][Full Text] [Related]
19. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.
Mesquita B; Veiga I; Pereira D; Tavares A; Pinto IM; Pinto C; Teixeira MR; Castedo S
BMC Cancer; 2005 Aug; 5():101. PubMed ID: 16095531
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]